568 results about "Terpenoid" patented technology

A method of relieving analgesia and reducing inflammation using a cannabinoid delivery topical liniment composition containing from about 97.5% to about 99.5% by weight a 70% monohydric alcohol solution, and from about 0.5% to about 2.5% by weight of a synergistic cannabinoid mixture extracted from the female plant Cannabis sativa L, including in combination: 9-Tetrahydrocannabinol (delta-9-THC), 9-THC Propyl Analogue (THC-V), Cannabidiol (CBD), Cannabidiol Propyl Analogue (CBD-V), Cannabinol (CBN), Cannabichromene (CBC), Cannabichromene Propyl Analogue (CBC-V), Cannabigerol (CBG), terpenoids, and flavonoids. The liniment is applied topically, preferably by spraying, and the constituents of the mixture are absorbed through the skin and interact with cannabinoid receptors in the body and tissues of a human patient to produce therapeutic analgesic and anti-inflammatory effects without undesirable psychotropic side effects.

The present invention relates to an oral composition which includes an organoleptically suitable carrier and an amount of a terpenoid and a flavonoid, dispersed in the carrier, which is effective to prevent or treat dental caries, dental plaque formation, gingivitis, candidiasis, dental stomatitis, aphthous ulceration, or fungal infection. The invention also relates to various uses of oral compositions, containing a terpenoid, a flavonoid, or both, such uses include: inhibiting the activity of surface-bound glusosyltransferase; treating or inhibiting dental caries, gingivitis, candidiasis, denture stomatitis; inhibiting the accumulation of microorganisms on an oral surface; and/or treating or inhibiting aphthous ulcerations on an oral surface.

The present invention generally relates to transgenic moss. One aspect of the invention provides a transgenic moss cell that produces or accumulates a terpenoid compound. Another aspect of the invention provides for methods of producing a terpenoid compound through culturing of the transgenic moss.

An antimicrobial composition, including a synergistic combination of three or more agents as an active ingredient. Each of the three or more potentiating agents can be selected from the following types of compounds: sequestering agents, carbohydrates and carbohydrate derivatives, terpenes/terpenoids, amines and amine derivatives, plant-derived oils, sulfonates, phenols, fatty acids, dibenzofuran derivatives, organo isothiocyanates, quaternary ammonium compounds, peroxides and peroxide donors, and macrolide polyenes. At least two of the three or more potentiating agents are not of the same type of compound. The antimicrobial composition can have strong antimicrobial efficacy in control of microorganisms having resistance to currently used antimicrobials.

The present invention is a method for the biosynthesis of hundreds of compounds, mainly found in the cannabis plant. The starting material for these compounds can be any biological compound that is used/produced in a biological organism from the sugar family starting materials or other low cost raw materials processed via enzymes or within organisms to give final products. These final products include, but are not limited to: cannabinoids, terpenoids, stilbenoids, flavonoids, phenolic amides, lignanamides, spermidine alkaloids, and phenylpropanoids. Specifically, the present invention relates to the regular/modified/synthetic gene(s) of select enzymes are processed and inserted into an expression system (vector, cosmid, BAC, YAC, phage, etc.) to produce modified hosts. The modified host is then optimized for efficient production and yield via manipulation, silencing, and amplifying inserted or other genes in the host, leading to an efficient system for product.

Cosmetic compositions containing terpenoids along with a 4-substituted resorcinol derivative exhibit improved storage stability and oxidative stability.

The invention concerns a method for producing terpenes of interest in plants having glandular trichomes, as well as plants useful for producing said terpenes of interest. Said plants comprise a sequence encoding a heterologous terpene synthase under the control of a promoter enabling it to be specifically expressed in the trichomes. Moreover, the pathway for producing endogenous diterpenes is preferably blocked in the trichomes of the plants, to increase the flow in the heterologous pathway. The secretion of heterologous terpenes is spontaneous resulting in easy collection. The present invention also concerns plants exhibiting a blocked production of a compound having antibiotic properties at the surface of leaves exhibiting enhanced efficiency of transformation by a bacterium.

The invention relates to a mixed gel applied to injection and a preparation method thereof. The mixed gel of the invention is characterized by comprising polyaspartic acid terpenoid gel particle, cross bonding hyaluronic acid gel particle and hyaluronic acid or salt solution thereof, wherein, the volume of the polyaspartic acid terpenoid gel particle accounts for 5-80%, the volume ratio of the cross bonding hyaluronic acid gel particle and hyaluronic acid or salt solution thereof ranges from 1:19-19:1; the preparation method of the mixed gel has the following steps: respectively preparing the polyaspartic acid terpenoid gel particle and cross bonding hyaluronic acid gel particle; mixing evenly the particles with hyaluronic acid dissolved in the isosmotic solution after full swelling and balancing in isosmotic solution, sterilizing and packaging the mixture to obtain the finished product. The mixed gel of the invention can be used to prepare injection for beauty care and medical treatment and has the characteristics of long hold time and little side effect.

A device and process for the vacuum pyrolization of scrap tires to produce a pyrolytic oil from which valuable terpenes such as limonene and pulegone may be extracted and purified.

There is shown a method of purifying glacial acetic acid containing terpene and terpenoid impurities. Substantially dry acetic acid containing terpene and terpenoid impurities is combined with water and a suitable organic solvent, which is substantially immiscible with acetic acid and water, to form a separating composite extraction medium having a weight ratio of acetic acid:water of at least 1:1. The components are separated into an organic phase and an aqueous acid phase, with the terpene and terpenoid impurities concentrated in the organic phase, and with the aqueous acid phase purified of terpene and terpenoid impurities. The purified aqueous acid phase is recovered, and the purified acetic acid is dried.

A lighter fluid composition usable for starting barbecues and the like that comprises naturally occurring combustible materials, which is clean burning and results in low volatile organic compound (VOC) emission during combustion, which is biodegradable and easily disposable, and which burns with a pleasant aroma and does not impart any unpleasant hydrocarbon odor or flavor to food cooked on a barbecue. The composition preferably comprises between approximately 0.5 weight percent and approximately 90 weight percent of a terpene or terpenoid oil, and between approximately 0.5 weight percent and approximately 98.5 weight percent of short chain alcohol, between approximately 0.5 weight percent and approximately 60 weight percent of water, between approximately 0.1 weight percent and approximately 10 weight percent of surfactant, and between approximately 0.5 weight percent and approximately 10 weight percent of thickening agent. The preferred terpene preferably comprises d-limonene or a citrus derived oil containing d-limonene such as cold-pressed orange oil. The preferred alcohols are methanol and ethanol. The preferred surfactant is a non-ionic detergent or detergents, and the preferred thickener is a pH controllable slightly cross-linked polyacrylic acid material.

The present invention relates to a novel pharmaceutical composition for serotonin reuptake inhibition, wherein the composition comprises pentacyclic terpenoid glycosides, preferably asiaticoside and madecassoside optionally along with excipients. Also the present invention relates to a process of preparation of novel pharmaceutical composition for serotonin reuptake inhibition, wherein the process comprising steps of: (a) obtaining extract from the plant Centella asiatica; (b) treating the extract with the solvents to remove fatty substances, chlorophyll and other colorants; (c) purifying the extract through HPLC to obtain the eluted solvent; and (d) concentrating the eluted solvent to arrive at the composition. The invention also relates to the use of a composition comprising pentacyclic terpenoid glycosides, preferably asiaticoside and madecassoside optionally along with excipients to manufacture a medicament for serotonin reuptake inhibition in a subject in need thereof.

The invention discloses a gene promoter of ginseng PgPDR3 responded by methyl jasmonate and an application thereof. The sequences of the gene promoter of the ginseng PgPDR3 are shown in SEQ ID NO.1, or are the DNA sequences of which the homology with SEQ ID NO.1 is over 99%. According to the invention, a Genomewalker technology is adopted to clone, later the sequences of the gene promoter of the PDR transport protein is obtained, and then the expression vector Pcambia1301-ProPDR3::GUS of the promoter is built; if the promoter in the transgenic tobacco drives the GUS to express, and can be controlled by ginsenoside, salicylic acid, gibberellins and abscisic acid, the promoter participates in the transport and accumulation of the ginsenoside, which provides a basis for cloning the gene of key control recording factor in the ginsenoside transport signal pathway and controlling the transport and accumulation of the terpenoid, such as ginsenoside; and fine plants containing rich ginsenoside can be obtained by using a method for controlling or improving the ginseng and other plants via the promoter or the derivative thereof.

The present invention provides an ophthalmic composition which stabilizes the tear film during wearing contact lens, prevents eye dryness, imparts a favorable sensation in using, is highly convenient with no risk of misuse and shows a high efficiency in the course from manufacturing to sales. More specifically, the present invention provides a wetting solution—eye drops for contact lenses comprising (A) one or more member (s) selected from the group consisting of a cellulose-based polymer, a vinyl-based polymer, polyethylene glycol and dextran; and (B) a terpenoid.

The invention relates to recombinant expression of a taxadiene synthase enzyme and a geranylgeranyl diphosphate synthase (GGPPS) enzyme in cells and the production of terpenoids.

The invention relates to a group of glycosyl transferases and applications of the glycosyl transferases. Particularly, the invention provides applications of glycosyl transferases gGT25, gGT13, gGT30, gGT25-1, gGT25-3, gGT25-5, gGT29, gGT29-3, gGT29-4, gGT29-5, gGT29-6, gGT29-7, 3GT1, 3GT2, 3GT3 and 3GT4, and derived peptides of the glycosyl transferases in glycosylation catalysis and new saponin synthesis of terpenoids. The glycosyl transferases can specifically and efficiently catalyze hydroxyl glycosylation of C-20 bit and/or C-6 bit and/or C-3 of a tetracyclic triterpenoid compound substrate, and/or transfers the glycosyl groups from glycosyl donors to the first glycosyl groups of the C-3 bit and C-6 bit of the tetracyclic triterpenoid compound to extend a carbohydrate chain. The glycosyl transferases disclosed by the invention can also be applied to building synthetic rare ginsenosides and a plurality of novel ginsenosides and derivatives of the ginsenosides.

A personal care product is provided which includes an unsaturated organic material with at least one olefinic double bond susceptible to degradation into a color bearing substance, the unsaturated material being selected from C₁₀-C₅₀ terpenoids and C₁₂-C₄₈ unsaturated fatty compounds selected from the group consisting of fatty alcohols, fatty acids, fatty acid glycerides, fatty acid salts and combinations thereof, a substituted urea as a stabilization agent to prevent color body formation, and a cosmetically acceptable carrier. Particularly useful as a stabilizing agent is hydroxyethyl urea.

The invention discloses a system and a method for analyzing polycyclic terpane in a petroleum geological sample. The system comprises a central processing unit, a mass spectrograph and a chromatograph, wherein the central processing unit is connected with the chromatograph through the mass spectrograph; the chromatograph comprises a vaporizing chamber and two chromatographic columns with different polarities; the sample enters the two chromatographic columns in turn for separation after passing through the vaporizing chamber in the chromatograph; each separated component substance enters the mass spectrograph in turn to form fragment ions; and the central processing unit qualitatively and quantitatively analyzes the component according to the distribution characteristic of the fragment ions and forms a chromatographic mass spectrum image. In the system and the method, by preferably and effectively combining the two chromatographic columns with different polarities, tricyclic terpenoids, tetracyclic terpenoids and pentacyclic terpenoids in saturated hydrocarbon component of crude oil or rock extract are effectively separated and qualitatively and quantitatively analyzed on the basis of optimized modulation period and analysis conditions.

The invention discloses an application of iridoids in preparing drugs for promoting nerve cell proliferation and/or differentiation and a method for treating diseases related to nerve cell proliferation and/or differentiation by using the same.

The invention relates to a terpenoid and an application thereof in medicines, and in particular relates to a new terpenoid, or an isomer, a medicinal salt, a hydrate or a solvate thereof, and an application thereof in medicines. Specifically, the invention relates to a terpenoid as shown in a general formula (I), or an isomer, a medicinal salt, a hydrate or a solvate thereof, and the application of the terpenoid, and the isomer, the medicinal salt, the hydrate or the solvate of the terpenoid in preparing drugs for treating renal/kidney diseases (RKD), insulin resistance, diabetes, complications related to diabetes, endothelial dysfunction, nonaalcoholic fatty liver diseases or cardiovascular diseases (CVD).